IPM Take
This Commission could have been written for the current IPM debate. Its message is uncomfortable: precision oncology can improve care, but broad genomic expansion without evidence, workforce, reimbursement, data infrastructure and equity safeguards can create cost and complexity faster than population benefit. The answer is not less precision medicine. It is more disciplined implementation.
Executive Summary
A major Lancet Oncology Commission published in the October issue concludes that access to cancer genomics and precision oncology remains deeply unequal both between and within countries. It warns that genomic research and clinical trials remain concentrated in high-income settings and populations of predominantly European ancestry; that fragmented data systems restrict learning; and that the most consistent clinical gains still occur in a relatively limited number of well-validated biomarker–treatment pairings. The Commission proposes a resource-stratified implementation framework, health-system readiness assessment, workforce competency framework, monitoring and evaluation structure, and principles for responsible data sharing.
Why it matters
- Policymakers: Buying sequencing capacity is not the same as building a precision-oncology system.
- Patients / advocates: Unequal testing creates unequal access to guideline-indicated treatment.
- Diagnostics / pathology: Testing needs quality standards, interpretation capacity and a defined clinical pathway.
- Payers / HTA bodies: Broad profiling needs evidence that the information generated changes outcomes and creates value.
Precision oncology has won the intellectual argument.
Almost everyone now agrees that cancer biology matters, biomarkers matter and treatment should become more individual.
The implementation argument is nowhere near settled.
The new Lancet Oncology Commission cuts through a problem the field has spent years politely avoiding: genomic capability is expanding faster than many health systems can use it well.
The result is a paradox.
A country can own sequencers and still lack precision oncology.
It can produce molecular reports without enough molecular pathologists. It can identify targets without reimbursing the treatment. It can offer comprehensive profiling while failing to test patients for a small number of biomarkers that already have strong clinical evidence. It can build databases that cannot talk to one another. It can call all of this innovation.
The Commission also makes an important distinction between possibility and proven value. Some biomarker-treatment pairings deliver substantial, reproducible benefit. Others remain much less certain. Comprehensive profiling and tumour-agnostic approaches can help selected patients, but broad population benefit cannot simply be assumed.
That should be politically liberating.
The answer does not need to be “sequence everything everywhere tomorrow.”
It can be: build the evidence-based core first; measure system readiness; strengthen workforce and data capacity; expand as value becomes demonstrable; and make equity a design condition rather than a later correction.
Precision medicine does not fail when a sequencing machine is absent.
It fails when the information cannot travel from specimen to decision to treatment.
